Konstantina Kyritsi

Konstantina Kyritsi

Auto-generated profile, based on publicly available information

Konstantina Kyritsi

Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
LKLindsey Kennedy
Lindsey Kennedy
GCGuido CARPINO
Guido CARPINO
TOTravis Owen
Travis Owen
LCLudovica Ceci
Ludovica Ceci
DKDebjyoti Kundu
Debjyoti Kundu
Gianfranco AlpiniGianfranco Alpini
Gianfranco Alpini

19 November 2020 in Hepatology
Verified
Journal Article
Closed access
NWNan Wu
Nan Wu
LBLeonardo Baiocchi
Leonardo Baiocchi
TZTianhao Zhou
Tianhao Zhou
LKLindsey Kennedy
Lindsey Kennedy
LCLudovica Ceci
Ludovica Ceci
Gianfranco AlpiniGianfranco Alpini
Gianfranco Alpini

20 February 2023 in Hepatology
Verified
Journal Article
Closed access
NWNan Wu
Nan Wu
TZTianhao Zhou
Tianhao Zhou
GCGuido CARPINO
Guido CARPINO
Leonardo BaiocchiLeonardo Baiocchi
Leonardo Baiocchi
KKKonstantina Kyritsi
Konstantina Kyritsi
Gianfranco AlpiniGianfranco Alpini
Gianfranco Alpini
Background and Aims: Secretin (SCT) and secretin receptor (SR, only expressed on cholangiocytes within the liver) play key roles in modulating liver phenotypes. Forkhead box A2 (FoxA2) is required for normal bile duct homeostasis by preventing the excess of cholangiocyte proliferation. Short-term administration of the SR antagonist (SCT 5–27) decreased ductular reaction and liver fibrosis in bile duct ligated and Mdr2−/− [primary sclerosing cholangitis (PSC), model] mice. We aimed to evaluate the effectiveness and risks of long-term SCT 5–27 treatment in Mdr2−/− mice. Approach and Results: In vivo studies were performed in male wild-type and Mdr2−/− mice treated with saline or SCT 5–27 for 3 months and human samples from late-stage PSC patients and healthy controls. Compared with controls, biliary SCT/SR expression and SCT serum levels increased in Mdr2−/− mice and late-stage PSC patients. There was a significant increase in ductular reaction, biliary senescence, liver inflammation, angiogenesis, fibrosis, biliary expression of TGF-β1/VEGF-A axis, and biliary phosphorylation of protein kinase A and ERK1/2 in Mdr2−/− mice. The biliary expression of miR-125b and FoxA2 decreased in Mdr2−/− compared with wild-type mice, which was reversed by long-term SCT 5–27 treatment. In vitro, SCT 5–27 treatment of a human biliary PSC cell line decreased proliferation and senescence and SR/TGF-β1/VEGF-A axis but increased the expression of miR-125b and FoxA2. Downregulation of FoxA2 prevented SCT 5–27–induced reduction in biliary damage, whereas overexpression of FoxA2 reduced proliferation and senescence in the human PSC cell line. Conclusions: Modulating the SCT/SR axis may be critical for managing PSC.

9 May 2022 in Cells
Verified
Journal Article
Open access
PDF file
RMRomina Mancinelli
Romina Mancinelli
LCLudovica Ceci
Ludovica Ceci
LKLindsey Kennedy
Lindsey Kennedy
Heather FrancisHeather Francis
Heather Francis
VMVik Meadows
Vik Meadows
AFAntonio Franchitto
Antonio Franchitto
Background & aims: Cholangiocytes are the target cells of liver diseases that are characterized by biliary senescence (evidenced by enhanced levels of senescence-associated secretory phenotype, SASP, e.g., TGF-β1), and liver inflammation and fibrosis accompanied by altered bile acid (BA) homeostasis. Taurocholic acid (TC) stimulates biliary hyperplasia by activation of 3′,5′-cyclic cyclic adenosine monophosphate (cAMP) signaling, thereby preventing biliary damage (caused by cholinergic/adrenergic denervation) through enhanced liver angiogenesis. Also: (i) α-calcitonin gene-related peptide (α-CGRP, which activates the calcitonin receptor-like receptor, CRLR), stimulates biliary proliferation/senescence and liver fibrosis by enhanced biliary secretion of SASPs; and (ii) knock-out of α-CGRP reduces these phenotypes by decreased cAMP levels in cholestatic models. We aimed to demonstrate that TC effects on liver phenotypes are dependent on changes in the α-CGRP/CALCRL/cAMP/PKA/ERK1/2/TGF-β1/VEGF axis. Methods: Wild-type and α-CGRP−/− mice were fed with a control (BAC) or TC diet for 1 or 2 wk. We measured: (i) CGRP levels by both ELISA kits in serum and by qPCR in isolated cholangiocytes (CALCA gene for α-CGRP); (ii) CALCRL immunoreactivity by immunohistochemistry (IHC) in liver sections; (iii) liver histology, intrahepatic biliary mass, biliary senescence (by β-GAL staining and double immunofluorescence (IF) for p16/CK19), and liver fibrosis (by Red Sirius staining and double IF for collagen/CK19 in liver sections), as well as by qPCR for senescence markers in isolated cholangiocytes; and (iv) phosphorylation of PKA/ERK1/2, immunoreactivity of TGF-β1/TGF- βRI and angiogenic factors by IHC/immunofluorescence in liver sections and qPCR in isolated cholangiocytes. We measured changes in BA composition in total liver by liquid chromatography/mass spectrometry. Results: TC feeding increased CALCA expression, biliary damage, and liver inflammation and fibrosis, as well as phenotypes that were associated with enhanced immunoreactivity of the PKA/ERK1/2/TGF-β1/TGF-βRI/VEGF axis compared to BAC-fed mice and phenotypes that were reversed in α-CGRP−/− mice fed TC coupled with changes in hepatic BA composition. Conclusion: Modulation of the TC/ α-CGRP/CALCRL/PKA/ERK1/2/TGF-β1/VEGF axis may be important in the management of cholangiopathies characterized by BA accumulation.

19 January 2026 in Cells
Verified
Journal Article
Open access
PDF file
RMRomina Mancinelli
Romina Mancinelli
LCLudovica Ceci
Ludovica Ceci
LKLindsey Kennedy
Lindsey Kennedy
Heather FrancisHeather Francis
Heather Francis
VMVik Meadows
Vik Meadows
AFAntonio Franchitto
Antonio Franchitto
The journal retracts the article titled “The Effects of Taurocholic Acid on Biliary Damage and Liver Fibrosis Are Mediated by Calcitonin-Gene-Related Peptide Signaling”

16 June 2022 in Gastroenterology
Verified
Journal Article
Closed access
TZTianhao Zhou
Tianhao Zhou
LCLixian Chen
Lixian Chen
KKKonstantina Kyritsi
Konstantina Kyritsi
NWNan Wu
Nan Wu
WZWenjun Zhang
Wenjun Zhang
KSKeisaku Sato
Keisaku Sato